Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.